Pacific Avenue Capital Partners Establishes Paris France Office and Xavier Lambert Joins as Head of Europe to Lead Firm’s EU Expansion
Pacific Avenue Capital Partners, LLC (“Pacific Avenue”), a Los Angeles-headquartered private equity firm focused on corporate divestitures, carve-outs, and other complex situations in the middle market, announced today the opening of a European office in Paris, France. The office will be led by Xavier Lambert, who joins the firm as Managing Director – Head of Europe.
Opening a Paris office underscores Pacific Avenue's continued focus on being a solutions provider to corporate sellers globally. With increasing carve-out and divestiture activity globally, and a growing number of Pacific Avenue’s deals with international operations, establishing a presence in Europe is a natural step in fulfilling the firm’s strategy. The addition of Mr. Lambert will expand the firm’s international footprint and add capabilities to serve global corporate sellers and Pacific Avenue businesses with international operations.
"Expanding our footprint in Europe marks a pivotal milestone in Pacific Avenue’s growth as a global leader focused on corporate divestitures and carve-outs," said Chris Sznewajs, Founder and Managing Partner of Pacific Avenue. "It became clear that as the go-to carve-outs provider, having a solution that allows us to participate globally was critical. Establishing an office and having a presence in Europe affirms our commitment to execute complex transactions regardless of geography. Our EU efforts will be led by Xavier Lambert, a highly accomplished professional with significant experience in middle market carve-outs and divestitures across the European continent. We are confident in his ability to lead and drive our European efforts. It’s a pleasure to welcome him to Pacific Avenue.”
Mr. Lambert brings a wealth of experience to Pacific Avenue. Prior to Pacific Avenue, he was with OpenGate Capital for more than 12 years, where he served as a Principal in the firm’s Paris office and was responsible for due diligence and executing European acquisitions across sectors such as Aerospace & Defense, Building Products, and Metals, with shared responsibility for Chemicals and Materials. Mr. Lambert holds a Master of Science in Management from EM Lyon Business School.
“I am thrilled to join Pacific Avenue and drive its European expansion,” said Mr. Lambert. “The firm’s focus on middle market corporate divestitures and commitment to unlocking value through operational improvement aligns perfectly with what I have done throughout my career. I look forward to building a strong foundation for Pacific Avenue’s future growth in Europe and meeting the needs of Corporate Sellers and portfolio company operations in a global environment.”
Pacific Avenue is currently investing from its first institutional fund, Pacific Avenue Fund I, L.P. (“Fund I”), which closed in April 2023. The firm has more than $1.9B in assets under management (AUM) as of September 30, 2024.
About Pacific Avenue Capital Partners
Pacific Avenue Capital Partners is a Los Angeles-headquartered private equity firm focused on corporate divestitures and other complex situations in the middle market. Pacific Avenue has extensive M&A and operations experience, allowing the firm to navigate complex transactions and unlock value through operational improvement, capital investment, and accelerated growth. The members of the Pacific Avenue team have closed over 105 transactions, including over 40 corporate divestitures, across a multitude of industries throughout their combined careers. Pacific Avenue takes a collaborative approach in partnering with strong management teams to drive lasting and strategic change while assisting businesses in reaching their full potential. For more information, please visit www.pacificavenuecapital.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209743291/en/
Contacts
Stephen Fishleigh
sfishleigh@gregoryfca.com
+44 7904 114 002
Philip Nunes
pnunes@gregoryfca.com
+1 617 777 0998
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom